# US 2014/0154215 A1 · Herpes virus strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154215 A1
- Document ID: US20140154215A1
- Status: Published application
- Kind: A1
- Application number: 14/174,521
- Filed: 2014-02-06
- Published: 2014-06-05
- Earliest claimed: 2000-01-21
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Robert S. COFFIN
- Web page: https://patentgrep.com/patent/US20140154215A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/763: Herpes virus
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/86: Viral vectors
- C12N 15/869: Herpesviral vectors
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C12N 2710/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.

## Claims

### Claim 1

A herpes virus which comprises a gene encoding an immunomodulatory protein, which lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene and which is replication competent in tumour cells.

### Claim 2 (depends on 1)

A virus according to claim 1 wherein said immunomodulatory gene is a cytokine, a chemokine or a protein capable of regulating T cell proliferation.

### Claim 3 (depends on 2)

A virus according to claim 2 wherein said cytokine is GM-CSF, said chemokine is RANTES or said protein is B7.1, B7.2 or CD40L.

### Claim 4 (depends on 1)

A virus according to claim 1 which encodes two or more immunomodulatory proteins.

### Claim 5 (depends on 1)

A virus according to claim 1 which further lacks a functional gene encoding ICP6, glycoprotein H or thymidine kinase.

### Claim 6 (depends on 1)

A virus according to claim 1 which further lacks a gene encoding functional copy of a protein capable of inhibiting dendritic cell function.

### Claim 7 (depends on 6)

A virus according to claim 6 in which said protein capable of inhibiting dendritic cell function is UL43 or vhs.

### Claim 8 (depends on 1)

A virus according to claim 1 which is a strain of herpes simplex virus 1 or 2.

### Claim 9 (depends on 1)

A virus according to claim 1 which is a non-laboratory virus strain.

### Claim 10 (depends on 9)

A virus according to claim 9 wherein said non-laboratory strain: (a) has undergone one year or less in culture since isolation of its unmodified precursor strain from its host, or (b) has undergone 100 or less cycles of serial passage since isolation of unmodified precursor strain from its host, or (c) has a greater ability than a reference laboratory strain with equivalent modifications to infect or replicate in a tumour cell, to kill tumour cells, or to spread between cells in tissue, or (d) has substantially the ability of its unmodified precursor strain in respect of one or more of the properties defined in (c).

### Claim 11 (depends on 10)

A virus according to claim 10 wherein, in (c), said greater ability in a statistically significant greater ability; or wherein, in (d), substantially the same ability is the same ability or at an ability not statistically different.

### Claim 12 (depends on 10)

A virus according to claim 10 wherein the non-laboratory strain is an HSV strain and the reference strain is HSV1 strain 17+, HSV1 strain F as HSV1 strain KOS with equivalent modifications to the non-laboratory strain.

### Claim 13 (depends on 1)

A virus according to claim 1 which is derived from HSV1 JSI as deposited at the European collection of cell cultures (ECAAC) under provisional accession number 01010209.

### Claim 14 (depends on 1)

A virus according to claim 1 for use in a method of treatment of the human or animal body by therapy.

### Claim 15 (depends on 1)

Use of a virus according to claim 1 in the manufacture of a medicament for the treatment of cancer.

### Claim 16 (depends on 15)

Use according to claim 15 wherein said medicament is for direct intra-tumoral inoculation.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising as active ingredient a virus according to claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 18 (depends on 1)

A method of treating a tumour in an individual in need thereof by administering to said individual an effective amount of a virus according to claim 1.

### Claim 19

An agent for treating cancer comprising a herpes virus which comprises a gene encoding an immunomodulatory cytokine, which lacks a functional ICP34.5-encoding gene and a functional ICP47 encoding gene and which is replication competent in tumour cells.

### Claim 20

HSV1 strain JSI as deposited as the European Collection of Cell. Cultures (ECACC) under provisional accession number 01010209, or an HSV1 strain derived therefrom.

### Claim 21

A method of treating cancer in an individual in need thereof by administering to a tumor in said individual a therapeutically effective amount of a herpes simplex virus which: (i) comprises an immunostimulatory protein; (ii) lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene; and (iii) is replication competent in infected tumor cells.

### Claim 22 (depends on 21)

The method of claim 21 wherein said virus kills infected tumor cells by oncolysis and stimulates an anti-tumor immune response.

### Claim 23 (depends on 21)

The method of claim 21 wherein tumor cells infected with said virus and non-infected tumor cells are killed.

### Claim 24 (depends on 23)

The method of claim 23 wherein said virus is administered to a primary tumor and tumor cells in the primary tumor and tumor cells elsewhere that have spread from the primary tumor site are killed.

### Claim 25 (depends on 23)

The method of claim 23 wherein said cancer is selected from the group consisting of prostate, breast, liver, endometrial, bladder, colon or cervical carcinoma, melanoma, lymphoma, glioma and sarcoma.

### Claim 26 (depends on 23)

The method of claim 23 wherein said cancer is selected from the group consisting of prostate, breast, lung, liver, endometrial, bladder, colon or cervical carcinoma, adenocarcinoma, melanoma, lymphoma, glioma and sarcoma.

### Claim 27 (depends on 21)

The method of claim 21 wherein said virus is administered by direct intratumoral inoculation.

### Claim 28 (depends on 21)

The method of claim 21 wherein said virus is administered to a blood vessel supplying the tumor.

### Claim 29 (depends on 21)

The method of claim 21 wherein said immunostimulatory protein is GM-CSF.

### Claim 30 (depends on 21)

The method of claim 21 wherein said immunostimulatory protein is a cytokine, chemokine or protein capable of regulating T cell proliferation.

### Claim 31 (depends on 21)

The method of claim 21 wherein said virus further lacks a functional gene encoding ICP6, glycoprotein H or thymidine kinase.

### Claim 32 (depends on 21)

The method of claim 21 wherein said virus is a strain of herpes simplex virus 1 or 2.

### Claim 33 (depends on 21)

The method of claim 21 wherein said virus is a clinical isolate.

### Claim 34 (depends on 33)

The method of claim 33 wherein said clinical isolate is derived from HSV1 JS1 as deposited at the European collection of cell cultures (ECAAC) under accession number 01010209.

### Claim 35

A herpes simplex virus which: (i) comprises a gene encoding an immunostimulatory protein selected from GM-CSF and a chemokine; (ii) lacks a functional ICP34.5 encoding gene and a functional ICP47 encoding gene; and (iii) is replication competent in infected tumor cells.

### Claim 36 (depends on 35)

The virus of claim 35 wherein said immunostimulatory protein is GM-CSF.

### Claim 37 (depends on 35)

The virus of claim 35 which comprises a functional UL43 gene and/or a functional gene encoding vhs.

### Claim 38 (depends on 35)

The virus of claim 35 which further lacks a functional gene encoding ICP6, glycoprotein H or thymidine kinase.

### Claim 39 (depends on 35)

The virus of claim 35 which is a strain of herpes simplex virus 1 or 2.

### Claim 40 (depends on 35)

The virus of claim 35 which is a clinical isolate.

### Claim 41 (depends on 35)

A pharmaceutical composition comprising as active ingredient a virus according to claim 35 and a pharmaceutically acceptable carrier or diluent.

### Claim 42 (depends on 36)

A pharmaceutical composition comprising as active ingredient a virus according to claim 36 and a pharmaceutically acceptable carrier or diluent.

### Claim 43 (depends on 42)

A pharmaceutical composition according to claim 42, wherein the virus is derived from HSV1 JS1 as deposited at the European collection of cell cultures (ECAAC) under accession number 01010209.
